*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2026 | Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · preclinical | PMID 41490200 |
| 2025 | Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice British journal of pharmacology · preclinical | PMID 40692165 |
| 2025 | Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing Bioinorganic chemistry and applications · preclinical | PMID 40496623 |
| 2024 | ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke Biomedicines · preclinical | PMID 39767736 |
| 2022 | Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models ACS chemical neuroscience · preclinical | PMID 35080861 |
| 2021 | Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats Neuropeptides · preclinical | PMID 33418449 |
| 2018 | Pharmacological Aspects of Neuro-Immune Interactions Current pharmaceutical design · preclinical | PMID 28875850 |
| 2018 | Effects of Semax on the Default Mode Network of the Brain Bulletin of experimental biology and medicine · preclinical | PMID 30225715 |
| 2018 | [The efficacy of semax in the tretament of patients at different stages of ischemic stroke] Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · human | PMID 29798983 |
| 2017 | Semax, an analog of ACTH((4-7)), regulates expression of immune response genes during ischemic brain injury in rats Molecular genetics and genomics : MGG · preclinical | PMID 28255762 |
| 2016 | Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties Journal of inorganic biochemistry · preclinical | PMID 27586814 |
| 2016 | Semax prevents learning and memory inhibition by heavy metals Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections · preclinical | PMID 27411820 |
| 2014 | The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis BMC genomics · preclinical | PMID 24661604 |
| 2010 | Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia Cellular and molecular neurobiology · preclinical | PMID 19633950 |
| 2010 | [Nootropic and analgesic effects of Semax following different routes of administration] Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova · preclinical | PMID 21268834 |
| 2007 | Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10 Neuroscience letters · preclinical | PMID 17353092 |
| 2006 | Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain Journal of neurochemistry · preclinical | PMID 16635254 |
| 2005 | Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents Neurochemical research · preclinical | PMID 16362768 |
Semax (Semax (Met-Glu-His-Phe-Pro-Gly-Pro; ACTH(4-10) analogue)). Synthetic heptapeptide analogue of ACTH(4-10) without corticotropic activity. Increases BDNF/NGF expression, modulates dopaminergic/serotonergic systems; studied for stroke and cognitive indications in Russian clinical literature.
Commonly discussed uses: cognitive support / neuroprotection (research), stroke recovery (clinical in Russia). There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Synthetic heptapeptide analogue of ACTH(4-10) without corticotropic activity. Increases BDNF/NGF expression, modulates dopaminergic/serotonergic systems; studied for stroke and cognitive indications in Russian clinical literature.
Reported considerations: anecdotal: well tolerated; nasal irritation; overstimulation at high dose. There is both human and animal/preclinical research, though the depth and quality vary by indication. Registered as a medicine in Russia; not approved in AU/US/UK. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low 200mcg, typical intranasal 300-600mcg/day, high higher in clinical stroke protocols. Administration: intranasal, subcutaneous. Half-life: short (minutes); central effects longer.
Australian status: Not ARTG-registered; research. Registered as a medicine in Russia; not approved in AU/US/UK. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: intranasal pre-mixed; SC 2ml BAC per 5-10mg; storage: refrigerated.
Commonly discussed combinations (anecdotal for unapproved compounds): Semax + Selank (nootropic stack, anecdotal). Stacking increases interaction/safety uncertainty.